CTI Molecular Imaging Inc.'s PETNet Solutions subsidiary and GlaxoSmithKline (GSK) have signed an agreement to collaborate in the area of positron emission tomography (PET) imaging.
PETNet will provide facilities and services to GSK at a pre-clinical research site in Mt. Vernon, United Kingdom, including PET isotopes to the facility for pre-clinical research purposes. PETNet also will have the option -- at GSK's sole discretion -- to license diagnostic PET probes that are developed by GSK.
CTI Solutions President Thomas J. Hook said with the "strategy at PETNet to develop new proprietary probes, this initiative could augment our existing R &D pipeline. We see this market as a very attractive growth opportunity that will extend the use of PET well beyond today's clinical uses."